State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou 510515, China.
Viruses. 2023 May 31;15(6):1297. doi: 10.3390/v15061297.
The monoclonal antibody (mAb)-based treatment is a highly valued therapy against COVID-19, especially for individuals who may not have strong immune responses to the vaccine. However, with the arrival of the Omicron variant and its evolving subvariants, along with the occurrence of remarkable resistance of these SARS-CoV-2 variants to the neutralizing antibodies, mAbs are facing tough challenges. Future strategies for developing mAbs with improved resistance to viral evasion will involve optimizing the targeting epitopes on SARS-CoV-2, enhancing the affinity and potency of mAbs, exploring the use of non-neutralizing antibodies that bind to conserved epitopes on the S protein, as well as optimizing immunization regimens. These approaches can improve the viability of mAb therapy in the fight against the evolving threat of the coronavirus.
单克隆抗体（mAb）治疗是一种对抗 COVID-19 的高度有价值的疗法，特别是对于那些对疫苗可能没有强烈免疫反应的人。然而，随着奥密克戎变体及其不断进化的亚变体的出现，以及这些 SARS-CoV-2 变体对中和抗体的显著耐药性的发生，mAbs 面临着严峻的挑战。未来开发对病毒逃逸具有更高抗性的 mAbs 的策略将包括优化针对 SARS-CoV-2 的靶向表位，提高 mAbs 的亲和力和效力，探索使用结合 S 蛋白保守表位的非中和抗体，以及优化免疫方案。这些方法可以提高 mAb 疗法在对抗冠状病毒不断演变的威胁方面的生存能力。
